

PHARMANUTRA S.P.A.: BOARD OF DIRECTORS RESOLVES TO CONVENE THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING ON APRIL 16, 2025

Pisa, March 4, 2025 – The Board of Directors of PharmaNutra S.p.A. (MTA; Ticker PHN), a leading pharmaceutical company in the field of iron-based nutritional supplements, met today and resolved to convene the Company's ordinary and extraordinary Shareholders' Meeting, in a single call, on April 16, 2025, at 11am. The ordinary Shareholders' Meeting will be called to deliberate on (i) the approval of the financial statements as of December 31, 2024, (ii) the Section II of the report on the remuneration policy and compensation paid, (iii) the appointment of the Board of Statutory Auditors, (iv) the authorization to purchase and dispose of treasury shares, and (v) the assignment of the engagement to certify the compliance of the sustainability reporting. In the extraordinary session, the Shareholders' Meeting will deliberate on the proposed amendments to the bylaws.

The notice of call will be published within the terms and in accordance with the applicable regulations.

It is also noted that the Board of Directors' meeting for the approval of the draft financial statements as of December 31, 2024, will be held, as per the financial calendar, on March 14, 2025.

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements with the SiderAL® brand, where it can claim important Sucrosomial® Technology patents, and is considered one of the top players in the sector of medical devices dedicated to the restoration of joint capacity thanks to the Cetilar® brand, now on the market also with Cetilar® Nutrition, a line of supplements designed for those who practice sport constantly. Over the years the Group - present abroad in over 89 countries - has developed precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

[PharmaNutra.it](https://www.pharmanutra.it)

For further details:

PharmaNutra S.p.A.

Via Campodavella, 1 - 56122 Pisa, Italy

Tel. +39 050 7846500

investorrelation@PharmaNutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan, Italy

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com